Know whether treatment is helping
“Is the medicine doing anything?”
- Designed to give a clear answer at each visit, in place of months of guessing
- Evidence that helps keep patients on a treatment that works for them
Creating a future where timely intervention is the norm.
Sciflux is developing blood tests that read the tiny particles your cells release as a fingerprint of disease. Our first test is for Alzheimer's, where doctors will be able to see whether treatment is working.
In development. Not yet available for clinical use.
people worldwide have developed dementia today.
One every 3 seconds. Source: Alzheimer's Disease International.
Imagine a parent slowly forgetting who you are. Families deserve to know whether treatment is helping.
Working with
Scripps ResearchResearch collaboration
Confido Medical CentreLead clinical partner
Supported by
PrototronWinning team, 2024
Today's blood tests tell you amyloid is there. Sciflux is built to show how the disease is changing.
Every cell releases tiny particles called extracellular vesicles, a snapshot of the cell that made them. Published research shows they change with Alzheimer's. We read thousands of them from a single blood sample and turn them into a fingerprint of disease.
- A routine blood drawA small sample from the draw the clinic already does. No spinal tap, no scanner.
- Read on our microfluidic chipThousands of particles from one sample, each one read individually.
- A fingerprint of diseaseMachine learning turns the readings into one quantitative profile.
- Change the clinic can act onEach result is compared with the patient's own baseline, so the neurologist sees what changed since the last visit.
Treatments have arrived. Monitoring hasn't.
The first drugs that slow Alzheimer's reached patients in the last few years. They cost tens of thousands per year, and clinicians still have no objective way to track how each patient responds.
3 sSomeone in the world develops dementia this often.
>86Mpeople live with early or mild Alzheimer's.
$1.3Tyearly global cost of dementia.
Illustration only, not patient data.
A number to guide each visit
“Send a sample, get a report card.”
- Designed to confirm and set a baseline alongside pTau217
- Built to track response against the patient's own baseline, in the existing blood draw
See response sooner
“Which patients are responding, and when?”
- A repeatable, quantitative readout for trial cohorts
- Built for more frequent readouts than imaging allows
A biophysicist and a hardware builder, friends for twenty years.
“The industry spent 30 years and billions to finally get treatments for Alzheimer's, and with them a real need to know whether they're working. That's the test we're building.”
CEO and co-founder
Silver Jõemetsa
PhD in biophysics from Chalmers and postdoc at Scripps Research. A decade of biomarker measurement experience.
COO and co-founder
Sten Krüüner
Mechanical and robotics engineer, veteran of three hardware startups: Cleveron, Milrem Robotics and ParcelSea. More than $50M in shipped products.
Advisers
- Diagnostics lab builderSenior diagnostics leader in global pharma. Has built a clinical diagnostics lab from the ground up through reimbursement.
- Microfluidics founderCo-founder and CTO of a microfluidics company, with several patent families.
- Clinician and machine learningMedical doctor with five years in primary care and three in clinical-trial regulation, plus experience in medical machine learning.
Partners
- Confido Medical Centre, EstoniaLead clinical partner
- University hospital, Norway · Medical university, South KoreaClinical partners
- Scripps Research, USAResearch collaboration
- US academic Alzheimer's networkUpcoming
Alzheimer's first. Pan-neuro next. Natera for neuro.
Natera and Guardant Health turned blood-based cancer monitoring into reimbursed standard of care. We are taking the same lab route for neurodegeneration, starting where the science is strongest and the need is biggest.
158Alzheimer's drugs in clinical trials, about twice as many as a few years ago
~2MUS patients eligible for anti-amyloid treatment
>$900per test: the reimbursement precedent in cancer monitoring
- Proof of concept in human blood plasmaDone
- Analytical validation underwayNow
- Clinical validation with partner cohortsEthics submitted for the first clinical cohortNow
- US CLIA lab and lab-developed testDirect-pay and pharma revenue, then MolDX reimbursement. Parkinson's and ALS next.Next
Request the investor deck
Write to the founders for the deck, the data room and a call.
Email the founders